1. Transforming Real-World Data into Structured, Usable Intelligence: Using our enterprise-level RWD ecosystem, Zephyr built PRISM—an AI-enabled clinical inference engine that converts messy, multi-modal patient data into structured, inference-ready patient journeys. PRISM unlocks the full potential of RWD for scalable clinical insights, machine learning development, and validation.
2. Multi-Modal AI for Predictive Modeling and Expression Reconstruction: Zephyr’s AI models predict drug response and reconstruct gene expression from clinically available inputs such as NGS data from commercial LDTs and whole-slide images (WSI). These capabilities enable retrospective validation of treatment predictions across oncology, linking molecular and clinical outcomes in real-world settings.
3. Partner-Ready Software for Rapid Co-Development and Clinical Integration: Zephyr’s foundation models can be fine-tuned for new assets, diagnostics, or therapeutic areas using partner data—delivering bespoke, AI solutions that integrate as software directly into existing R&D and clinical workflows. Our infrastructure also supports rapid clinical intelligence queries and cohorting, empowering data-driven decision-making from discovery through commercialization.
Anshu Jain, MD
Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations—translating Zephyr’s AI and large-scale real-world data into solutions that help biopharma and diagnostic partners advance precision medicine for patients. Prior to Zephyr, Dr. Jain served as Chief Medical Officer at Aster Insights.
Dr. Jain has authored peer-reviewed publications in Nature Communications, Journal of Clinical Oncology (JCO), and JCO Clinical Cancer Informatics, and has served as a principal investigator for early- and late-phase oncology trials. He has advised the FDA Office of the Commissioner and the Oncology Center of Excellence, and provided clinical leadership to large-scale data initiatives including the NCI SEER program.
He serves on the Board of Directors of the Community Oncology Alliance, the Board of Advisors for the Duke Cancer Institute, and is an Assistant Professor at the Yale School of Medicine.
Dr. Jain trained in internal medicine and radiation oncology at the Massachusetts General Hospital and Columbia New York Presbyterian Hospital. He earned his M.D. with Highest Distinction from the University of Kentucky College of Medicine and a degree in Economics from Duke University.